LCL161

For research use only. Not for use in humans.

目录号：S7009

LCL161 Chemical Structure

CAS No. 1005342-46-0

LCL-161, 一种second mitochondrial activator of caspase (SMAC, 线粒体促凋亡蛋白)模拟物, 能有效地结合并抑制多种IAPs(i.e. XIAP, c-IAP)。

规格 价格 库存 购买数量  
RMB 1194.96 现货
RMB 3883.15 现货
RMB 8176.93 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的LCL161发表文献24篇：

产品安全说明书

IAP抑制剂选择性比较

生物活性

产品描述 LCL-161, 一种second mitochondrial activator of caspase (SMAC, 线粒体促凋亡蛋白)模拟物, 能有效地结合并抑制多种IAPs(i.e. XIAP, c-IAP)。
靶点
cIAP [1] XIAP [1]
体外研究

LCL161以高亲和力与凋亡抑制蛋白因子(IAPs)结合，并启动对cIAP1和cIAP2的破坏，其通过胱天蛋白酶的激活进一步诱导细胞凋亡。LCL161单独给药时适度抑制表达FLT3-ITD的细胞生长，IC50的范围为~0.5 μM (Ba/F3-FLT3-ITD 细胞)到~4 μM (MOLM13-luc+ 细胞)。观察到的LCL161抗D835Y突变体的效力相当高，测试抗Ba/F3-D835Y细胞时，IC50为~50 nM。LCL161 与PKC412结合治疗MOLM13-luc+细胞比其任何一个药剂单独使用具有更显著的细胞杀伤力，Calcusyn复合指数表明其具有协同作用。 PKC412和LCL161诱导MOLM13-luc+细胞的凋亡。PKC412 和 LCL161结合比其单独使用能够导致更高的细胞凋亡率。LCL161通过与PKC412阳性结合，抑制基质介导的表达FLT3的突变细胞的存活。LCL161抑制Ba/F3.p210细胞的生长，IC50为~100 nM。LCL161与ABL抑制剂，伊马替尼结合，能够协同抗BCR-ABL表达的细胞。对于在靶蛋白表达点突变的耐药细胞，LCL161也具有抵抗活性。1000 nM的LCL161能够大部分或完全杀死耐PKC412的Ba/F3衍生的细胞系，其在FLT3的ATP结合囊表达含有点突变的FLT3-ITD。100到1000 nM浓度的LCL161也表现出抗Ba/F3细胞的活性， Ba/F3细胞能够表达各种伊马替尼和尼罗替尼耐药的BCR-ABL点突变。[1] 对LCL161抗23细胞系的评估，通过儿科临床前测试计划(PPTP)在体外进行96小时。对23种测试PPTP细胞系中的其中3种，10 μM浓度下的LCL161能够抑制50%的生长。3种细胞系包括2种T细胞ALL细胞系(COG-LL-317和CCRF-CEM)，以及间变性大细胞淋巴瘤细胞系(Karpas-299)，CCRF-CEM和Karpas-299表现出较低的相对IC50值(分别为0.25和1.6 μM)。[2] LCL161对人体免疫亚群表现出免疫调节性能。用LCL161处理T淋巴细胞显著增强具有激活作用的细胞因子分泌，对 CD4和CD8 T细胞生存或分化的作用很小。LCL161处理外周血单核细胞，在体外合成多肽存在下，显著增强初始T细胞的启动。髓样树突状细胞在LCL161作用下表型成熟，表明降低了基于肿瘤抗原对抗疫苗的能力。这些作用可能通过观察到的典型和非典型NF-κB途径的激活介导，伴随LCL161导致抗凋亡分子上调。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LOX M{PpOWZ2dmO2aX;uJIF{e2G7 MlfqNVAxKG2pL3vn NF3STI85KGi{cx?= NXXP[4FLWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[0mDUEGg[IVoemGmYYTpc44hcW5iaIXtZY4hVE:[IHPlcIx{KHinbn;ndoFnfGWmIHnuJI1wfXOnIHH0JFExOCCvZz;r[{wheG9iYX\0[ZIhQCCqcoOgZpkhX2W|dHXyckBjdG:2dHnu[{BidmGueYPpdy=> NX[1flBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
LOX MkXkSpVv[3Srb36gZZN{[Xl? MUC4JIhzew>? NEH2T5ZRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBk[XOyYYPlJFMwPyCjY4TpeoF1cW:wIHnuJIh2dWGwIFzPXEBk\WyuczD4[Y5w\3KjZoTl[EBqdiCvb4Xz[UBi\nSncjC4JIhzeyCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= NUDDZm1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
MDA-MB-231 MVPGeY5kfGmxbjDhd5NigQ>? NET0Z2EzNjVidH:gNVAhfU1? M{PidFE6KGi{cx?= Mk\4Rolv\GmwZzDh[oZqdmm2eTD0c{BkUUGSMTDCTXI{KGSxbXHpckBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGTOSoFteGijIHzleoVtKGG2IEKuOUB1dyBzMDD1UUBi\nSncjCxPUBpenNiYomgSWxKW0F? NFrDeGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
BxPC3 MYrGeY5kfGmxbjDhd5NigQ>? MVOzMlMhfU1? M4PuelUh\GG7cx?= MUTQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCfHBEOyClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
HCT15 M{fGPGZ2dmO2aX;uJIF{e2G7 NIPjbmU{NjNidV2= NV7ET|JGPSCmYYnz NXHGO2xKWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYSgN{4{KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
SW620 MVTGeY5kfGmxbjDhd5NigQ>? NVjo[41vOS5zIIXN MkXyOUBl[Xm| MYnQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{BifCBzLkGgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
SW620 MkLFSpVv[3Srb36gZZN{[Xl? M3;BVlMvOyC3TR?= NH\CdmY2KGSjeYO= NXPSUZZNWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1d4MkCgZ4VtdHNiYYSgN{4{KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? M3nSWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
LOX MULGeY5kfGmxbjDhd5NigQ>? NF7QUIE{NjNidV2= MVGzJIRigXN? MYTQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMU3gh[2WubIOgZZQhOy5|IIXNJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYm= MkH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEO3PFIoRjJ2MEizO|gzRC:jPh?=
LS180 NUXqeox4TnWwY4Tpc44h[XO|YYm= MY[zMlMhfU1? NV\1OGl2PSCmYYnz NV7KSIRsWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFNzOECgZ4VtdHNiYYSgN{4{KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? M1TheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
H460 NH3keI9HfW6ldHnvckBie3OjeR?= MYmzMlMhfU1? MlX2OUBl[Xm| M3SyO3BwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMh[XRiMz6zJJVOKGGodHXyJFUh\GG7czDifUBOXFNiYYPzZZk> NGfvOVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
LOX NXrI[|BCTnWwY4Tpc44h[XO|YYm= NELoN2oyODBibXevb4c> MlnTPEBpenN? Mn;WVIxie22jIHPvcoNmdnS{YYTpc44hcW5iboXk[UBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKEyRWDDj[YxteyCjdDCxNFAhdWdxa3esJJBwKG2nYYP1doVlKGG2IEigbJJ{NCCFcDC9JFMvOyEQvF2u NXu3fJlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
SW620 M4jadGZ2dmO2aX;uJIF{e2G7 NWrVOGpRPSCmYYnz MYTJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDTW|YzOCClZXzsd{B1dyClb37heJVufW2jYj3pcoR2[2WmIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7LDDFR|kxKD1iNj62OkDPxE1w MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
LOX Mm\qSpVv[3Srb36gZZN{[Xl? M1;yRlExOCCvZz;r[y=> MXe4JIhzew>? M2niUWRzfWdidYD0ZYtmKGmwIIT1cY9zKG:oIH71[IUhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiCOT2igZ4VtdHNiYYSgNVAxKG2pL3vnMEBxdyCvZXHzeZJm\CCjdDC4JIhzeyxiRIL1[{B2eHSja3WgQUAyQC52IN88UU4> Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
SW620 NH7icJRHfW6ldHnvckBie3OjeR?= MlrKNk42KHWP NVPzNJczPSCmYYnz MYrJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDTW|YzOCClZXzsd{B1dyClb37heJVufW2jYj3pcoR2[2WmIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
LOX M2DHUGZ2dmO2aX;uJIF{e2G7 MWqxNFAhdWdxa3e= M3rSRlghcHK| NHTtXJpKdiC4aY\vJIlvcGmkaYTpc44hd2ZiWFnBVEBDUVJ{IHTvcYFqdiCrbjDoeY1idiCOT2igZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjZZNx[XOnIEOvO{Bi[3Srdnn0fUBifCBzMECgcYcwc2duIIDvJIFnfGW{IEigbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NVLN[2FFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
LOX M4HD[2Z2dmO2aX;uJIF{e2G7 MYqxNFAhdWdxa3e= NIe4OZY5KGi{cx?= M3vyWmlvKH[rdn:gbY5pcWKrdHnvckBw\iC[SVHQJGJKWjJiZH;tZYlvKGmwIHj1cYFvKEyRWDDj[YxteyC6ZX7v[5Ji\nSnZDDpckBvfWSnIH3veZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJINie3Cjc3WgN{84KGGldHn2bZR6KGG2IEGwNEBu\y:tZzygdI8h[W[2ZYKgPEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
MDA-MB-231 MV7GeY5kfGmxbjDhd5NigQ>? NUX0OYxPOC5|NzD0c{A{NjNidV2= MX2xPUBpenN? M4e2PGlvcGmkaYTpc44hd2ZiY1nBVFEwOiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBVVk[jbIDoZUBt\X[nbDDheEAxNjN5IITvJFMvOyC3TTDh[pRmeiBzOTDodpMh[nliRVzJV2E> NXT6VINXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
CHL1 MoPuSpVv[3Srb36gZZN{[Xl? MWSwMlQhfG9iMUCgeW0> MknENlghcHK| NHq0VmZKdmirYnn0bY9vKG:oIHPJRXAyKGmwIHj1cYFvKEOKTEGgZ4VtdHNiYYSgNE41KHSxIEGwJJVOKGGodHXyJFI5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NYL3dmVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
SKMES1 NFXtWlZHfW6ldHnvckBie3OjeR?= NXPVbmRZOi53IIXN MnfYOUBl[Xm| M4PKS3BwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCqdX3hckBUU02HU{GgZ4VtdHNiYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? M3jhWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
Capan1 MkfWSpVv[3Srb36gZZN{[Xl? NHH4d2szNjVidV2= MVq1JIRigXN? NGPYUZVRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iaIXtZY4hS2GyYX6xJINmdGy|IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 NGKwSoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
AGS NGPoWWNHfW6ldHnvckBie3OjeR?= M3juUlIvPSC3TR?= NXnQS|RPPSCmYYnz Mk\4TY5lfWO2aX;uJI9nKHOnboPpeIl7[XSrb36gc4YhcHWvYX6gRWdUKGOnbHzzJJRwKGOxbnH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
U118MG M2P6bGZ2dmO2aX;uJIF{e2G7 NWL4ZXZXOi53IIXN NW\6TWw5PSCmYYnz NU[1TWFTWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[XCxcITvd4l{KGmwIHj1cYFvKFVzMUjNS{Bk\WyuczDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= M1jBTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
PC3 NXzjWGpMTnWwY4Tpc44h[XO|YYm= MlLLNk42KHWP MkC5OUBl[Xm| NYnjWnhmUW6mdXP0bY9vKG:oIIPlcpNqfGm8YYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KHSxIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgUXRUKGG|c3H5 NWTF[nU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
CCRF-CEM NXX3OGpbSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NX;YOI1sSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyxiR1m1NEA:KDBwMkWg{txONg>? NVizRWhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|U2OjZpPkK4OFM2PTJ4PD;hQi=>
MDA-MB-231 Ml7KSpVv[3Srb36gZZN{[Xl? MUGyJIhzew>? M4L5dmlv\HWldHnvckBw\iClSVHQNUBl\We{YXTheIlwdiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFIhcHK|LDDFR|UxKD1iMD6wNFA1KM7:TT6= M{nXWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEmyN|E4Lz5{OES5NlMyPzxxYU6=
MDA-MB-231 MU\DfZRwfG:6aXPpeJkh[XO|YYm= M1W5fVczKGi{cx?= NUXaeoF6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDFR|UxKD1iMD6wNFc5KM7:TT6= NGC4bpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES5NlMyPyd-Mki0PVI{OTd:L3G+
HEK293 MmHjSpVv[3Srb36gZZN{[Xl? NGjM[IYzKGi{cx?= NY\2Z4U6UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBHVEGJLYTh[4dm\CC[SVHQJEh2dmuwb4fuJI9zcWerbjmgbY51\XKjY4Tpc44hf2m2aDDmeYxtKGynbnf0bEB2dnSjZ3fl[EBk[XOyYYPlMVkh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bi\nSncjCyJIhzeyCkeTDpcY12dm:ycnXjbZBqfGG2aX;uJIF{e2G7LDDFR|UxKD1iMD6wN|Uh|ryPLh?= NUizU3Z4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PVI{OTdpPkK4OFkzOzF5PD;hQi=>
MDA-MB-231 M3z2[mFvfGm2dX3vdkBie3OjeR?= MnizN|AhdWdxa3e= MmH2NlQh\GG7cx?= NFu3UHRCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIjlco9oemGodHXkJIlvKEKjbHKvZ{BUS0mGIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKGe{b4f0bEBqdmirYnn0bY9vKGG2IEOwJI1oN2upIHHkcYlvcXO2ZYLl[EB3cWFib4LhcEBo[X[jZ3Wg[o9zKDJ2IHThfZM> NFX5N4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES5NlMyPyd-Mki0PVI{OTd:L3G+
MDA-MB-231 M{HNZmZ2dmO2aX;uJIF{e2G7 Mn;GNkBpenN? MlP0TY5lfWO2aX;uJI9nKGmwdILhZ4VtdHWuYYKgZ2lCWDFiZHXndoFl[XSrb36gbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB{IHjyd{whUUN3MDC9JFAvODByNDFOwG0v M2nUZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEmxOlAxLz5|MEC5NVYxODxxYU6=
MDA-MB-231 NF\5N4lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NIK0dGI4OiCqcoO= M1HR[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhSWyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjByN{ig{txONg>? NVn0b2tnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVE3ODBpPkOwNFkyPjByPD;hQi=>
HEK293 MnztSpVv[3Srb36gZZN{[Xl? NVzF[IdyOiCqcoO= MnzDTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDGUGFINXSjZ3fl[EBZUUGSIDj1cotvd3ewIH;ybYdqdiliaX70[ZJi[3Srb36ge4l1cCCodXzsJIxmdme2aDD1cpRi\2enZDDjZZNx[XOnLUmg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDh[pRmeiB{IHjyd{BjgSCrbX31co9xemWlaYDpeIF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5yM{Wg{txONg>? NVvCPYVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVE3ODBpPkOwNFkyPjByPD;hQi=>
SKOV3 Ml7SRZBweHSxc3nzJIF{e2G7 M2XVWVQ5KGi{cx?= M2qxcGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iU1vPWlMh[2WubIOgZZN{\XO|ZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W[2ZYKgOFghcHK|IHL5JGlv[3WFeYTlJHM{KGyrdnWtZ4VtdCCjbnHsfZNqeyxiRVO1NEA:KDBwMECxJO69VS5? NULXOowyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GwPVU{QDZpPkOxNFk2Ozh4PD;hQi=>
SKOV3 M33UbWFxd3C2b4Ppd{Bie3OjeR?= M2PmcVI1KGi{cx?= MoHMTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBi\nSncjCyOEBpenNiYomgTY5kfUO7dHWgV|MhdGm4ZT3j[YxtKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMEOg{txONg>? NUTGSZBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GwPVU{QDZpPkOxNFk2Ozh4PD;hQi=>
BL21(DE3) NUe0fopvTnWwY4Tpc44h[XO|YYm= MXOyJIhzew>? MlmwSIl{eGyjY3Xt[Y51KG:oIHLpc5RqdnmuYYTl[EBCXlCIIH\yc40hVi22ZYLtbY5idCCKaYOgeIFo\2WmIILlZ49u[mmwYX70JIh2dWGwIGjJRXAuSkmUMzDkc41icW5iKEK1N{B1dyB|NEegdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BqdmO3YnH0[YQh\m:{IEKgbJJ{KGK7IFTFUGZKSSxiSVO1NEA:KDBwMES4JO69VS5? M3m0Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
BL21(DE3) MmjhSpVv[3Srb36gZZN{[Xl? NVq3VIFUQCCqcoO= NVLvem5sTGm|cHzhZ4Vu\W62IH;mJIJqd3SrbonsZZRm\CCDVmDGJIZzd21iTj30[ZJucW6jbDDIbZMhfGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHhKSVBvQlnSN{Bld22jaX6gLFI2OyC2bzCzOFchemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV|KTDj[YxteyCrbnP1ZoF1\WRiZn;yJFghcHK|IHL5JGRGVE[LQTygTWM2OCB;IECuNFU{KM7:TT6= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB7NUO4Okc,OzFyOUWzPFY9N2F-
A549 M1W0W2Z2dmO2aX;uJIF{e2G7 NITsVWMyKHWP NHrMcHo{KGi{cx?= NHj1ZoFKdmS3Y4Tpc44hd2ZiY1nBVFIh\GWpcnHkZZRqd25iaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY1nBVFIheHKxdHXpckBt\X[nbDDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV3MEG1OUc,OzF3NUCxOVU9N2F-
SK-MEL-28 NVvOdmo{TnWwY4Tpc44h[XO|YYm= MlLuNUB2VQ>? MX:zJIhzew>? NHnCVHdKdmS3Y4Tpc44hd2ZiY1nBVFEh\GWpcnHkZZRqd25iaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBkUUGSMTDwdo91\WmwIHzleoVtKGG2IEGgeW0hcW6ldXLheIVlKG[xcjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NELLT3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUW1NFE2PSd-M{G1OVAyPTV:L3G+
SK-MEL-28 M2W2XmZ2dmO2aX;uJIF{e2G7 NV;CZlcxOSC3TR?= MWCzJIhzew>? NF\p[4dKdmS3Y4Tpc44hd2ZiY1nBVFIh\GWpcnHkZZRqd25iaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBkUUGSMjDwdo91\WmwIHzleoVtKGG2IEGgeW0hcW6ldXLheIVlKG[xcjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NHP2SXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUW1NFE2PSd-M{G1OVAyPTV:L3G+
HEK293T NFHCUJpHfW6ldHnvckBie3OjeR?= M1j2SFExKHWP Mnj5OkBpenN? MY\Dc5ZidGWwdDDibY5lcW6pIHHm[olvcXS7IITvJGhCNUKLUkOg[I9u[WmwIH;mJHhKSVBiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBj[W6mIHnueIVve2m2eTDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NUHtfms2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVAyPTVpPkOxOVUxOTV3PD;hQi=>
A549 NHuyNVZHfW6ldHnvckBie3OjeR?= NXrUemU2OSC3TR?= MlXHN{BpenN? MUfJcoR2[3Srb36gc4Yh[0mDUEGg[IVoemGmYYTpc44hcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[0mDUEGgdJJwfGWrbjDs[ZZmdCCjdDCxJJVOKGmwY4XiZZRm\CCob4KgN{BpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NUiwOXRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVAyPTVpPkOxOVUxOTV3PD;hQi=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / surivivin ; 

PubMed: 27737687     


A549 and H460 cells were treated for 48 h with 0-20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting. β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
Growth inhibition assay
Cell viability; 

PubMed: 27737687     


Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
体内研究 LCL161显著增强PKC412抑制Ba/F3-FLT3-ITD-luc+细胞体内生长的能力。LCL161能够与标准化疗剂，阿糖胞苷和阿霉素阳性结合，抗FLT3-ITD表达细胞和D835Y表达细胞。Nilotinib与LCL161结合能够实现抑制白血病生长的累加作用。LCL161 (100 毫克/千克)增强高适度剂量nilotinib (100毫克/千克)对患有白血病小鼠的体内作用。[1] 通过儿科临床前测试程序(PPTP)测试CL161(口服给药，一周两次)在体内(30 或 75 毫克/千克[实体瘤] 或100 毫克/千克 [ALL])的作用。LCL161诱导显著的EFS在大约三分之一实体瘤异种移植物(osteosarcoma and glioblastoma) 中的分布差异，但不影响ALL异种移植物中的情况。没有观察到可评价客观疗效者。在体内，LCL161对儿科临床前模型研究表现出有限的单剂量活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验：

[1]
- 合并
  • Cell lines: 人 T 细胞 ALL 细胞系 COG-LL-317
  • Concentrations: ~10 μM
  • Incubation Time: 96小时
  • Method:

    使用DIMSCAN进行体外测试


    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (199.74 mM)
Water Insoluble
Ethanol '20 mg/mL warmed

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 500.63
化学式

C26H33FN4O3S
CAS号 1005342-46-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03111992 Completed Drug: PDR001|Drug: CJM112|Drug: LCL161 Multiple Myeloma Novartis Pharmaceuticals|Novartis December 18 2017 Phase 1
NCT01934634 Unknown status Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel Metastatic Pancreatic Cancer US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC March 2014 Phase 1
NCT01968915 Completed Drug: LCL161|Drug: Paclitaxel Neoplasms Novartis Pharmaceuticals|Novartis November 2013 Phase 1
NCT01617668 Completed Drug: LCL161|Drug: paclitaxel Breast Cancer Novartis Pharmaceuticals|Novartis August 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

IAP Signaling Pathway Map
Tags: 购买LCL161 | LCL161供应商 | 采购LCL161 | LCL161价格 | LCL161生产 | 订购LCL161 | LCL161代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID